Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prospective Study of White Blood Cells

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04838171
Recruitment Status : Recruiting
First Posted : April 8, 2021
Last Update Posted : April 8, 2021
Sponsor:
Information provided by (Responsible Party):
Quell Therapeutics Limited

Brief Summary:
The purpose of this study is to investigate white blood cells from volunteering donors to support the development of engineered regulatory T cell therapies.

Condition or disease Intervention/treatment
Autoimmune Diseases Inflammation Rejection; Transplant, Liver Other: White blood cell and blood collection

Layout table for study information
Study Type : Observational
Estimated Enrollment : 10 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Investigation of White Blood Cells to Support the Development of Engineered Regulatory T Cell (Treg) Therapies
Actual Study Start Date : March 24, 2021
Estimated Primary Completion Date : December 2024
Estimated Study Completion Date : December 2024

Group/Cohort Intervention/treatment
Specimen collection to support development of engineering Treg Other: White blood cell and blood collection
Mononucleocytes will be collected via apheresis




Primary Outcome Measures :
  1. WBC characterisation to support the development of engineered regulatory T cells. [ Time Frame: 5 years ]
    number, type and function of white blood cells in healthy controls and in patients



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Volunteers willing to provide white blood cells for research.
Criteria
No additional inclusion/ exclusion criteria will be applied by Quell other than those specified by the consenting institutions.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04838171


Contacts
Layout table for location contacts
Contact: David Collin +4(0)2070969012 contact@quell-tx.com

Locations
Layout table for location information
United Kingdom
Quell Investigator Site 01 Recruiting
London, United Kingdom
Sponsors and Collaborators
Quell Therapeutics Limited
Layout table for additonal information
Responsible Party: Quell Therapeutics Limited
ClinicalTrials.gov Identifier: NCT04838171    
Other Study ID Numbers: QEL-RP-001
First Posted: April 8, 2021    Key Record Dates
Last Update Posted: April 8, 2021
Last Verified: April 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Autoimmune Diseases
Inflammation
Pathologic Processes
Immune System Diseases